Laman UtamaBHC • NYSE
Bausch Health Companies Inc
$7.54
13 Jan, 11:47:14 PG GMT-5 · USD · NYSE · Penafian
SahamSekuriti tersenarai ASIbu pejabat di CA
Tutup sebelumnya
$7.88
Julat hari
$7.45 - $7.80
Julat tahun
$3.96 - $11.46
Permodalan pasaran
2.72B USD
Bilangan Purata
1.27J
Nisbah P/E
-
Hasil dividen
-
Markah Perubahan Iklim CDP
D
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD)Sep 2024Perubahan T/T
Hasil
2.51B12.15%
Perbelanjaan pengendalian
1.27B13.29%
Pendapatan bersih
-85.00J77.51%
Margin untung bersih
-3.3979.93%
Pendapatan bagi setiap syer
1.129.34%
EBITDA
866.00J8.93%
Kadar cukai berkesan
-338.10%—
Jumlah aset
Jumlah liabiliti
(USD)Sep 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
719.00J-5.39%
Jumlah aset
26.54B-1.94%
Jumlah liabiliti
26.78B-1.89%
Jumlah ekuiti
-242.00J—
Syer tertunggak
367.80J—
Harga kepada buku
-2.47—
Pulangan pada aset
5.13%—
Pulangan pada modal
6.37%—
Perubahan bersih dalam tunai
(USD)Sep 2024Perubahan T/T
Pendapatan bersih
-85.00J77.51%
Tunai daripada operasi
405.00J43.62%
Tunai daripada pelaburan
-102.00J94.60%
Tunai daripada pembiayaan
-189.00J-110.41%
Perubahan bersih dalam tunai
127.00J-33.85%
Aliran tunai bebas
606.75J261.43%
Perihal
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell. Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada. Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Diasaskan
1959
Pekerja
20,270
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama